This site is intended for U.S. healthcare professionals.
|Prevnar 20 was studied in previously vaccinated patients1,2|
|Study description||Phase 3 randomized, open-label clinical trial|
|Countries||United States and Sweden|
Safety and immunogenicity of Prevnar 20 in patients previously vaccinated with:
|Risk factors||Healthy and immunocompetent adults with stable underlying conditions, including chronic cardiovascular disease, chronic pulmonary disease, renal disorders, diabetes, chronic liver disease, and medical risk conditions and behaviors (eg, smoking) that are known to increase the risk of serious pneumococcal pneumonia and IPD.|
|Response measures||There is no noninferiority analysis of Study 6.|
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2022 Pfizer Inc. All rights reserved.
Please click for Prevnar 20™ Full Prescribing Information.
This is an interstitial message to prompt a HCP before they login.
This can differ in its messaging based on a login being presented via a modal or via a page redirect.
Buttons for this interstitial are provided for confirming and declining this interstitial and can be configured via the traits.